

The role of cognitive reserve and clinical symptoms in the association between genetic liability for educational attainment and functioning in first-episode psychosis: a mediation analysis

RUNNING TITLE: Educational attainment and functioning in FEP

Derek Clougher^{1,2,¥}, Àlex G Segura^{2,3,¥}, Maria Florencia Forte^{1,2,4}, Gisela Mezquida^{2,3,4}, Manuel J Cuesta^{5,6}, Eduard Vieta^{1,2,*}, Silvia Amoretti^{1,2,4,7,*}, Antonio Lobo^{2,8}, Ana González-Pinto^{2,9,10}, Covadonga M. Díaz-Caneja^{2,11}, Alexandra Roldán^{2,12}, Giovanna Fico^{1,2}, Elena de la Serna^{2,13}, Daniel Bergé^{2,14}, Patricia Gassó^{2,3}, Natalia Rodríguez^{2,3}, Norma Verdolini¹⁵, Alfonso Tortorella¹⁶, Giulia Menculini¹⁶, Marta Ribasés^{2,7}, Miguel Bernardo^{2,4}, Sergi Mas^{2,3}, PEPs Group.

¹ Bipolar and Depressive Disorders Unit, Hospital Clinic of Barcelona, Institute of Neurosciences, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain.

² Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Barcelona, Spain.

³ Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.

⁴ Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, University of Barcelona, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Spain.

⁵ Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain.

⁶ IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

1

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI.

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

⁷ Group of Psychiatry, Mental Health and Addictions, Vall d'Hebron Research Institute (VHIR), Psychiatric Genetics Unit, Vall d'Hebron Research Institute (VHIR), Barcelona, Catalonia, Spain.

⁸ Department of Medicine and Psychiatry. Zaragoza University. Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.

⁹ Araba University Hospital, Bioaraba Research Institute, Spain.

¹⁰ University of the Basque Country (UPV-EHU), Spain.

¹¹ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, Madrid, Spain.

¹² Department of Psychiatry, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

¹³ Department of Child and Adolescent Psychiatry and Psychology, 2017SGR881, Institut Clinic de Neurociències, Hospital Clínic Universitari, IDIBAPS, Department of Medicine, University of Barcelona, Barcelona, Spain.

¹⁴ Hospital del Mar Medical Research Institute; Universitat Pompeu Fabra, MELIS Department, Barcelona, Spain.

¹⁵ Local Health Unit Umbria 1, Department of Mental Health, Mental Health Center of Perugia, Italy.

¹⁶ Section of Psychiatry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

‡ Derek Clougher and Àlex G Segura should be considered joint first author

*** Corresponding authors:**

Eduard Vieta

Silvia Amoretti

E-mail address: evieta@clinic.cat

E-mail address: silvia.amoretti@vhir.org

Department of Psychiatry and Psychology. Clinical Institute of Neuroscience. Hospital Clinic of Barcelona, Villarroel, 170. 08036 Barcelona, Spain.

Tel.: +34 93 227 54 00; fax: +34 93 227 92 28

Abstract

Background: Polygenic risk scores for educational attainment (PRS_{EA}), cognitive reserve (CR), and clinical symptoms are associated with psychosocial functioning in first-episode psychosis (FEP). Nevertheless, the mechanisms underlying their complex interaction is yet to be explored. This study aimed to assess the mediating role of CR and clinical symptoms, both negative (NS) and positive (PS), on the interrelationship between PRS_{EA} and functionality, one year after a FEP.

Methods: A total of 162 FEP patients underwent clinical, functional, and genetic assessments. Using genome-wide association study (GWAS) summary results, PRS_{EA} were constructed for each individual. Two mediation models were explored. The parallel mediation model explored the relationship of PRS_{EA} with functionality through CR and clinical symptoms, NS, and PS. The serial mediation model tested a causal chain of the three mediators: CR, NS and PS. Mediation analysis was performed using the PROCESS function V.4.1 in SPSS V.22.

Results: A serial mediation model revealed a causal chain for PRS_{EA} > CR > NS > Functionality ($\beta=-0.35$, 95%CI [-0.85, -0.04], $p<0.05$). The model fit the data satisfactorily (CFI=1.00; RMSEA=0.00; SRMR= 7.2×10^{-7}). Conversely, in a parallel mediation, none of the three mediators significantly mediated the relationship between PRS_{EA} and functionality and the model poorly fit the data (CFI=0.30; RMSEA=0.25; SRMR=0.11).

Conclusions: Both CR and NS mediate the relationship between PRS_{EA} and functionality at one-year follow-up, using serial mediation analysis. This may be relevant for prevention and personalized early intervention to reduce illness impact and improve functional outcomes in FEP patients.

Key words: first-episode psychosis, polygenic risk score, functioning, cognitive reserve, negative symptoms

Introduction

First-episode psychosis (FEP) is characterised by functional impairments in social, occupational, and independent living activities and is a crucial period for early intervention to improve long-term prognosis (1,2). Achieving functional remission in FEP is a core clinical objective (3), yet recovery rates vary over the course of the illness (4–6), with long-term functioning impairments present even in patients in clinical remission (7–9). Several factors are believed to influence functioning in FEP patients, including genetic variability (2), negative symptoms (10–12), cognitive performance (13,14) and cognitive reserve (CR)(15,16).

Genetic variability is a potential modulator of prognosis in FEP (2) and is understood using polygenic risk scores (PRSs) (17). PRSs aggregate the effects of many genetic variants across the human genome into a single score and are used to predict the genetic disposition for developing a given disease, including mental disorders (18), while also overcoming certain limitations of candidate-gene strategies (2). In fact, PRSs demonstrated good discriminative ability of case-control status in FEP individuals (2,19). Schizophrenia and bipolar disorder PRSs have been linked to symptom severity, comorbid disorders, and cognitive impairments (20). A significant positive correlation between PRS and the Positive and Negative Syndrome Scale (PANSS) but not overall functioning was found in a sample of FEP individuals (21). Another study (22) failed to find an association between schizophrenia PRSs and functioning. In both studies, the inclusion of patients at different illness stages with varying symptomatology and small sample sizes may have reduced power to identify small effects. The PRS for educational attainment (PRS_{EA}) is based on the completed years of schooling and captures associated social, economic, and health outcomes (23). Lower educational attainment is associated with higher schizophrenia PRSs (24) and an overall higher frequency of copy number variants (CNVs) which are considered high risk for psychiatric disorders (25). Importantly, a higher PRS_{EA} was associated with lower symptom severity and better functionality suggesting increased

autonomy and better cognitive functioning (2), thus highlighting the potential protective properties of PRS_{EA}.

Cognitive reserve (CR) has also been considered a protective factor and is understood as the brain's ability to cope in response to pathology and delay the onset of the associated clinical, cognitive, and functional symptoms (26–30). In various psychiatric populations, including FEP, higher CR has been associated with later onset age, greater insight, and reduced illness severity in terms of symptoms, particularly negative symptoms, better cognitive performance, and functioning (15,31–34). Individual differences in CR could explain why people with similar disorders differ in their levels of functioning (30,35–38).

Research exploring PRSs and their associations with CR, clinical symptoms, and functioning following a FEP remains limited. Understanding the factors contributing to functional performance in FEP may contribute to early personalized intervention and person-focused therapy. The aim of this study was to investigate the mediating role of CR and clinical symptoms (negative and positive) on the interrelationship between genetic liability for educational attainment and functionality one-year post-FEP. We hypothesise that patients with higher PRS_{EA} will have higher CR and less clinical symptoms, thus better overall functionality at one-year follow-up.

Methods

Sample

335 FEP patients participated in the 'Phenotype-Genotype Interaction: Application of a Predictive Model in First Psychotic Episodes' (PEPs based on Spanish acronym) (39,40), a collaborative project between various members of the Spanish Research Network on Mental

Health (CIBERSAM) (41). This was a multicentre, naturalistic, prospective, longitudinal study. For comprehensive information regarding medication and sample diagnosis see Bioque et al. (42).

The PEPS study inclusion criteria were: 1) between 7 and 35 years at first evaluation; 2) < 12 months history of psychotic symptoms; 3) fluent Spanish, and 4) provide written informed consent. Exclusion criteria were: 1) intellectual disability according to DSM-IV-TR criteria; 2) history of head trauma with loss of consciousness, and 3) organic disease with mental repercussions.

Patients who provided blood samples for genetic analysis, passed the genetic quality control (see section: blood samples and genotyping), completed all assessments at one-year follow-up, were aged ≥ 16 years old (chosen cut-off point as this is the age at which most scales report adolescent-adulthood results), had self-reported European ancestry, belonged to the non-affective psychotic disorder diagnostic category and, additionally, had all the information needed to calculate CR, were included. To control for the potential loss of sample, we focused on symptomatology and functional data for a period of 1 year. **Supplementary Figure 1** depicts the selection process of the 162 patients with FEP.

The PEPs Project was approved by the Clinical Research Ethics Committee of all participating centres and was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice.

Written informed consent was obtained from all participants prior to inclusion in the study.

Assessments

Clinical, pharmacological and sociodemographic assessment. Relevant sociodemographic, clinical, and pharmacological data were collected for all participants. Sociodemographic data included age, sex, and education. Pharmacological treatment was based on international

consensus (43) and measured using chlorpromazine equivalents (CPZ). To calculate the duration of untreated psychosis (DUP), the number of days between the time taken from the initial onset of psychotic symptoms to beginning treatment for psychosis was calculated. The onset of psychotic symptoms was assessed with the Symptom Onset in Schizophrenia (SOS) scale (39,44), explored via interviews with the patient, medical records, and interviews with relatives.

Diagnoses were established using the Structured Clinical Interview for DSM (SCID-I-II) (45,46) according to DSM-IV criteria. The PANSS scale (47) was administered for the psychopathology assessment. Higher scores indicate greater symptom severity.

Although the PANSS is one of the most widely used measures of negative symptom severity, it has several limitations as it was not designed to evaluate negative symptoms exclusively (48). Thus, we also used the PANSS-Marder Factor Scores (49) as it has more restrictive criteria to assess positive and negative symptomatology. For the present study, the PANSS was solely used to understand the role of positive and negative symptoms in the sample as the literature has shown that cognitive reserve is highly associated with negative symptoms only (50), whereas functionality has been linked to both positive and negative symptoms (51). The sum of the following items of the PANSS were used to calculate the Positive Symptom Factor (PS): delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), stereotyped thinking (N7), somatic concerns (G1), unusual thought content (G9) and lack of judgment and insight (G12); and for the Negative Symptom Factor (NS): blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and conversation flow (N6), motor retardation (G7) and active social avoidance (G16).

Functional assessment. The Functioning Assessment Short Test (FAST) (52) evaluated overall functioning across the following six areas: autonomy, occupational functioning, cognitive functioning, management of personal finances, interpersonal relationships and leisure time. Higher scores indicate poorer functioning.

The Premorbid Adjustment Scale (PAS) (53) evaluates the achievement of developmental goals prior to the onset of psychotic symptoms and was administered retrospectively to assess premorbid adjustment. Information was obtained from the patients themselves and parents/close relatives. All participants completed the childhood and adolescence elements of this scale. Higher scores indicate worse premorbid adjustment.

Cognitive reserve assessment. Premorbid intelligence quotient (IQ), educational attainment level, and lifetime participation in leisure, social, and physical activities are the three most commonly proposed proxy indicators of CR in psychiatry, particularly in FEP (31,33,35,36,38) and were used to assess CR in this study. Estimated premorbid IQ was evaluated with the Vocabulary subtest of the Wechsler Adult Intelligence Scale-III (54) as a measure of crystallised intelligence. The total number of participants' completed years in education, as well as parents' educational level, were used to assess educational attainment level. The scholastic performance domain of the PAS scale was used to evaluate lifetime participation in leisure, social, and physical activities and by enquiring about involvement in social activities, their self-rated capacity to take part in physical activities and satisfaction with hobbies. Higher scores indicate better performance. A "Cognitive Reserve Score" was created via a Principal Components Analysis (PCA) for each subject with completed data for the three core proxy indicators.

Blood samples and genotyping. K2EDTA BD Vacutainer EDTA tubes (Becton Dickinson, Franklin Lakes, New Jersey) were used to collect blood samples, which were subsequently stored at -

20°C prior to shipment to the central laboratory for further analysis. The MagNA Pure LC DNA isolation kit – large volume and MagNA Pure LC 2.0 Instrument (Roche Diagnostics GmbH, Mannheim, Germany) supported DNA extraction and DNA concentration was determined by absorbance (ND1000, NanoDrop, Wilmington, Delaware). Specifically, 2.5 µg of genomic DNA was sent for genotyping at the Spanish National Genotyping Centre (CeGen) using Axiom™ Spain Biobank Array (developed in the University of Santiago de Compostela, Spain).

PRS calculation. Genotyping data were submitted to the Michigan Imputation Server (55), following the standard pipeline for Minimac4 software and setting a European population reference from build GRCh37/hg19, reference panel HRC 1.1 2016 and Eagle v2.4 phasing.

For PRS calculation, GWAS summary results from the Social Science Genetic Association Consortium were obtained. Based on our previous study (2) we selected the PRS_{EA} (1,131,881 individuals) (23), measured as the number of years of schooling that individuals completed. Higher scores reflect the genetic liability for higher educational attainment. Duplicated and unknown strand GWAS summary single-nucleotide polymorphisms (SNPs) were excluded.

Quality control was performed with PLINK v1.07 (56). Inclusion criteria for SNPs were minor allele frequency > 0.01, Hardy-Weinberg equilibrium $p > 10^{-6}$, marker missingness < 0.01 and imputation INFO > 0.8. Pruning was done using a window/step size of 200/50 kb and $r^2 > 0.25$. Sample quality control included individuals with heterozygosity values within three standard deviations (SD) from the mean, a missingness rate of < 0.01, matching chromosomal and database-labeled sex and relatedness $\pi\text{-hat} < 0.125$.

The PRS were constructed using PRS-CS, a method that implements a high-dimensional Bayesian regression to perform a continuous shrinkage of SNP effect sizes using GWAS summary statistics and an external linkage disequilibrium (LD) reference panel (57). The LD

reference panel was constructed using a European subsample of the UK Biobank (58). For the remaining parameters, the default options as implemented in PRS-CS were adopted.

A genetic principal component analysis (PCA) was performed to control population stratification (59) by means of the SNPRelate package, and the first 10 components were used as covariates in the statistical analyses including PRS.

Statistical Analysis

Normality of continuous variables was tested using the Kolmogorov–Smirnov and Shapiro–Wilk tests. The confounding effect on functionality of discrete variables was analyzed using a t-test and Pearson's correlation coefficient was used for continuous variables. Before testing the mediation hypothesis, we tested the relationship between mediators and the outcome variable using Pearson's correlation coefficient.

Mediation analysis tested whether the effect of a causal variable (PRS_{EA}) on an outcome variable (functionality, FAST scale score) is affected by one or more mediator variables (CR, NS, PS, and Marder PANSS Factor Scores) at one-year follow-up. The relationship between variables is described by three effects: (1) Total effect (c), the association between causal variable and outcome variable; (2) Direct effect (c'), the effect of the causal variable on the outcome variable, when controlling for the mediator variables; and (3) Indirect effect, the effect of the causal variable on the outcome variable via the mediator variable (60). Two mediation models were explored. A parallel mediation model explored the relationship of PRS_{EA} with functionality through CR, NS and PS. A serial mediation model tested a causal chain of the three mediators: CR, NS and PS. Based on clinical knowledge, we propose that genetic predisposition for educational attainment may be linked to higher CR, which in turn decreases clinical symptomatology and therefore increases functionality ($PRS_{EA} > CR > \text{Clinical symptoms} > \text{Functionality}$) (2,10,38). For each model we obtained the total effect, the direct effect, and

the total indirect effect of all mediator variables, as well as the indirect effect of each individual mediator or serial path.

The statistical significance of the indirect effect was tested with a nonparametric bootstrapping approach (5000 iterations) to obtain 95% confidence intervals. In these analyses, mediation is considered significant if the 95% bias corrected for the indirect effect does not include 0.

Analysis was performed using the PROCESS function V.4.1 in SPSS V.22. The model 4 (model as a parameter in the PROCESS function) was used for the parallel mediation model, and model 6 for the serial mediation models. To control for population stratification, all models were fitted by the first ten principal components of the PCA analysis. Model fit statistics were also reported using the following: a Comparative Fit Index (CFI) (satisfactory >0.90), a Root Mean Square Error of Approximation (RMSEA) (satisfactory <0.05), and a Standardized Root Mean Square Residual (SRMR) (satisfactory <0.08) (61). The fit indices were derived using the R package *lavaan* (62).

Results

Table 1 shows the characteristics of the sample with 70% male and a mean age of 24.7 (SD=5.4). The mean dose of antipsychotic medication was equivalent to 577.8 (SD=489.5) mg/day of CPZ, and the mean DUP was 98.7 (SD=128.2) days (14 weeks approximately).

Functionality, measured using the FAST total score, was negatively correlated with PRS_{EA} ($r=-0.21$, $p=0.004$) and CR ($r=-0.23$, $p=0.003$), and positively correlated with NS ($r=0.69$, $p<0.001$) and PS ($r=0.56$, $p<0.001$), indicating that higher PRS_{EA} and CR are associated with better functional outcome. In contrast, higher levels of NS and PS are correlated with worse functional outcome. As these correlations were significant, the conditions required to perform mediation analysis were fulfilled.

The total effect of PRS_{EA} on functionality was significant ($\beta=-3.27$, 95%CI [-5.62, -0.93], $p=0.006$). In the parallel mediation model (**Figure 1**), the direct effect was not significant ($p=0.077$), and a total indirect effect was present ($\beta=-1.74$, 95%CI [-3.27, -0.18], $p<0.05$) (**Table 2**). None of the three mediators significantly mediated the relationship between PRS_{EA} and functionality. Fitting indices also demonstrated that the model poorly fit the data (CFI=0.30; RMSEA=0.25; SRMR=0.11).

The serial mediation model hypothesizes a causal chain linking the three mediators in a specified order and direction flow. We propose that PRS_{EA} may be linked to higher CR, which in turn decreases clinical symptomatology and therefore increases functionality (**Figure 2**). Results show that the three mediators in the abovementioned causal order fully mediate the relationship between PRS_{EA} and functionality, as no direct effect was observed whereas the total indirect effect was significant (**Table 2**). Among the seven paths that could be inferred from the model, only the path including CR and NS as mediators was significant according to 5000 bootstrapped samples. Fitting indices indicated that the model fits the data satisfactorily (CFI=1.00; RMSEA=0.00; SRMR= 7.2×10^{-7}).

Discussion

The main finding of this study is that the serial mediation model demonstrated that CR and clinical symptoms, more specifically NS, mediate the relationship between PRS_{EA} and functionality at one-year follow-up. To the best of our knowledge, this is the first statistical model describing this causal chain of events, improving our understanding of previously observed clinical findings. Based on this causal relationship between variables, a parallel mediation model poorly fit the data. Our results provide evidence for the role of genetic liability in the cognitive and clinical aspects of FEP, further supporting findings for the association between PRS_{EA} (and not psychological PRSs) and cognition, illness course, and

functioning (2). In our serial model, a causal chain ($PRS_{EA} > CR > \text{Clinical symptoms} > \text{Functionality}$) was found.

In terms of CR, results indicate its potential genetic component. Genetic and environmental factors are both important in CR. Genetics determine individual aspects of functional brain processes, which can be influenced by the interaction of innate individual factors (e.g., in utero or genetically determined) as well as lifetime exposures. Conversely, environmental elements such as education, occupation, physical exercise, leisure activities, and social interaction are also influential (63–65). In this context, the protective effect of the genetics underlying cognitive features in the early progression of clinical manifestation after a FEP has been recently reported (2). As such, FEP individuals with an increased genetic predisposition for better cognitive functioning could be more resilient to the stressful effects of the psychotic episode and have a better prognosis (2). Equally, environmental factors are currently addressed in specific interventions enhancing CR in FEP and high-risk populations (66). Therefore, our results add to the previous research demonstrating the mediating effects of CR, while also including the genetic component and its influence in the relationship with clinical symptoms and functioning.

Regarding clinical aspects, different studies have shown that CR is closely linked with negative symptoms (50,67) and only one study (51) has found a relationship between CR and positive symptomatology; the authors described that CR partially mediates the relationship between positive symptoms and functioning. Notably, negative and cognitive symptoms are indeed the primary predictors of functioning at different stages of psychotic disorders (68,69), and appear to have a greater impact on functioning than positive symptoms (70,71). Several studies of the PEPs project have established the role of CR as a mediator of clinical and cognitive symptoms, as well as functionality (31,35,38,72). Amoretti et al. (15) found that higher levels of CR predict a better prognosis following a FEP and reiterates the need to consider the genetic component

of this disorder. Nevertheless, in this study, CR alone did not predict functionality. This may be due to its complex interplay with NS and PS which are believed to have a more direct impact upon functionality (10). Hence, CR may have a strong genetic basis which influences NS, PS, and functionality. Specifically, findings suggest that PRS_{EA} may lead to higher CR which in turn is linked to lower NS and therefore better functionality following a FEP (e.g., $PRS_{EA} > CR > NS > \text{Functionality}$). This finding is relevant for the application of PRS in personalised medicine which aims to improve early disease detection, as well as early prevention (73) and personalised intervention methods (74).

Certain limitations in the present study must be considered. Firstly, several constraints are associated with the use of the PANSS as it was not designed with the purpose of solely measuring negative symptoms (75). To account for this, we used the PANSS-Marder Factor Scores (48) which applies stricter criteria for assessing positive and negative symptomatology. Future studies may include specific scales to assess negative symptoms such as the Brief Negative Symptom Scale (BNSS) (76,77) to address this drawback. A similar limitation is seen in all studies measuring CR in psychiatric populations as at the time of conducting this study there were no validated tools to evaluate CR. The Cognitive Reserve Assessment Scale in Health (CRASH)(78) for adult population, and Cognitive Reserve Questionnaire for Adolescents (CoRe-A) (79) have since been designed and should be administered accordingly. Secondly, the limited sample size may increase the risk of reducing statistical power and the ability to detect small effects. As such, further research with larger sample sizes is required. Finally, the short follow-up period is a potential limitation in this study. Nonetheless, the present study is a naturalistic and multicentric study from the entire Spanish population and comprises the largest and best characterized first-episode sample of the country. Additionally, the PRSs were calculated with the largest GWAS from international consortiums ergo the genetic variants have a greater capacity to capture the genetic susceptibility of the phenotypes explored.

Furthermore, the specific PRS-CS method implemented ensures that the shrinkage of variant effect sizes allows the inclusion of all available SNPs in the PRSs and therefore avoids p-value thresholding.

Conclusions

This study provides a potential clinical explanation for the association between genetic predisposition for educational attainment and functional outcomes. We identified an influence of CR on NS in mediating the relationship between PRSEA and functioning in individuals with FEP. These results highlight the suitability and applicability of mediation models to explore the relationship between genetic and clinical data. Additionally, these results may be of significant clinical importance for two primary reasons. Firstly, we provide a clinical framework for clinicians by identifying a potential causal chain of events which can be part of the ongoing development of PRSs in precision psychiatry to further advance towards personalized interventions. Secondly, and based on these insights, the use of cognitive interventions could be recommended to enhance CR by focusing on mental stimulation (e.g., cognitive tasks), physical exercise, leisure activities, and social skills training (66, 80). This is clinically relevant given the importance of functional outcomes during the first years after a first-episode. To prevent severe forms of the disorder and a poorer prognosis, rapid identification, timing of treatment, and early interventions in first-episode patients are key factors in determining their prognoses and functional outcomes.

Acknowledgments

We are extremely grateful to all participants.

This study is part of a coordinated-multicentre Project, funded by the Ministerio de Economía y Competitividad (PI08/0208; PI11/00325; PI14/00612; PI18/00789), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional. Unión Europea. Una manera de hacer Europa, Centro de Investigación Biomédica en Red de salud Mental, CIBERSAM, by the CERCA Programme / Generalitat de Catalunya AND Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2021 SGR 01120). Departament de Salut de la Generalitat de Catalunya, en la convocatòria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. MB is also grateful for the support of the Institut de Neurociències, Universitat de Barcelona.

M. Bernardo thanks the support of the Fundació La Marató de TV3 (202205-10).

E. Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI15/00283; PI18/00805; PI21/00787) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2021 SGR 1358) and the project SLT006/17/00357, from PERIS 2016-2020 (Departament de Salut). CERCA Programme/Generalitat de Catalunya. This work was supported by La Marató-TV3 Foundation Grant (202234-30).

S. Amoretti has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded

by European Social Fund “Investing in your future”. This work was supported by La Marató-TV3 Foundation Grant (202234-32).

G. Fico received the support of a fellowship from "La Caixa" Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880019.

M. F. Forte received the support of a “Contratos predoctorales de formación en investigación en salud (PFIS22) (FI22/00185) from the Instituto de Salud Carlos III (ISCIII).

A. González-Pinto thanks the support of the Spanish Ministry of Science, Innovation and Universities PI21/00713, PI18/01055 integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Basque Government 2022111054. The study has been supported by a BITRECS project conceded to NV. BITRECS project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 754550 and from “La Caixa” Foundation.

We also would like to thank the authors of the PEPs group who participated in the development of this manuscript, namely, Jairo González-Díaz ^{4,17,18}, Lydia Fortea ⁴, Alvaro Andreu-Bernabeu ^{2,11}, Marta Ferrer-Quintana ^{2,11}, Judit Selma ^{2,12}, Olga Martínez-Piera ², Iñaki Zorrilla ^{2,9,10}, Itxaso Gonzalez-Ortega ^{2,9,10}, Concepción De-la-Cámara ^{2,8}, Pedro M Ruíz-Lázaro ^{2,8}, Juan Nacher ^{2,19}, Carlos Cañete ^{2,20}, Laura Martínez-Sadurní ¹⁴, Georgina Benet ¹⁴, Maria Serra-Navarro ^{1,2}, Clàudia Valenzuela¹, Josefina Castro-Fornieles ^{2,13}, Immaculada Baeza ^{2,13}, Fernando Contreras ^{2,21}, Teresa Bobes-Bascarán ^{2,22,23}, Leticia González-Blanco ^{2,22,24}, Rafael Segarra ^{2,25}, Arantzazu Zabala ^{2,25}, Ángeles Sánchez-Cabezudo ²⁶, Roberto Rodriguez-Jimenez ^{2,26,27}, Judith Usall ²⁸, Anna Butjosa ^{2,29}, Edith Pomarol-Clotet ^{2,30}, Maria Ángeles García-León ^{2,30}, Ibáñez A^{2,31}, Ana M. Sánchez-Torres ^{5,6}, Vicent Balanzá ^{2,32}

¹⁷ UR Center for Mental Health - CERSAME, School of Medicine and Health Sciences, Universidad del Rosario, Bogota DC, Colombia.

¹⁸ Clínica Nuestra Señora de la Paz, Bogota DC, Colombia.

¹⁹ Neurobiology Unit, Program in Neurosciences and Interdisciplinary Research Structure for Biotechnology and Biomedicine (BIOTECMED), Universitat de València, Biomedical Research Institute INCLIVA, Valencia, Spain.

²⁰ Department of Psychiatry, Hospital Clínico Universitario de Valencia; Facultad de Medicina, Universidad de Valencia, Valencia, Spain; Biomedical Research Institute INCLIVA, Valencia, Spain.

²¹ Bellvitge University Hospital. IDIBELL. Barcelona, Spain.

²² Servicio de Salud del Principado de Asturias (SESPA) Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, Spain.

²³ Department of Psychology, Universidad de Oviedo, Oviedo, Spain.

²⁴ Department of Psychiatry, Universidad de Oviedo, Oviedo, Spain.

²⁵ Cruces University Hospital, BioCruces Health Research Institute, University of the Basque Country (UPV/EHU), Vizcaya, Spain.

²⁶ Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.

²⁷ Universidad Complutense de Madrid (UCM), Madrid, Spain.

²⁸ Parc Sanitari Sant Joan de Déu, Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Sant Boi de Llobregat.

²⁹ Hospital Infanto-juvenil Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona.

³⁰ FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain.

³¹ Department of Psychiatry, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.

³² Department of Medicine, University of Valencia, Valencia, Spain.

Conflicts of interest

E. Vieta has received grants and served as consultant, advisor or CME speaker for the following entities (unrelated to the present work): AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, and Takeda.

M. Bernardo has been a consultant for, received grant/ research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda.

N. Verdolini has received financial support for CME activities and travel funds from the following entities (unrelated to the present work): Angelini, Janssen-Cilag, Lundbeck, Otsuka.

A. Tortorella has received research support from Lundbeck and served as speaker for Lundbeck and Angelini unrelated to the present work.

G. Menculini received travel grants from Angelini and Janssen.

C. De-la-Camara received financial support to attend scientific meetings from Janssen, Almirall, Lilly, Lundbeck, Rovi, Esteve, Novartis, Astrazeneca, Pfizer and Casen Recordati.

I. Baeza has received honoraria or travel support to attend conferences from Angelini, Janssen and Otsuka-Lundbeck; and grants from Instituto de Salud Carlos III, Spanish ministry of Health.

R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; S2017/BMD-3740), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen-Recordati, Angelini.

J. González is partly funded by a grant from Ministerio de Ciencia y Tecnología – Republica de Colombia (Convocatoria 885/2020) and has been an advisor/speaker for, or received travel support from Janssen, Eurofarma, Servier, Sanofi, Lilly, and Pfizer.

A. Ibáñez has received research support from or served as speaker or advisor for Janssen-Cilag, Lundbeck and Otsuka.

The rest of the authors report no biomedical financial interests or potential conflicts of interest.

References

1. Griffiths SL, Wood SJ, Fowler D, Freemantle N, Hodgekins J, Jones PB, et al. Improved social functioning following social recovery therapy in first episode psychosis: Do social cognition and neurocognition change following therapy, and do they predict treatment response? *Schizophr Res.* 2021 Feb 1;228:249–55.
2. Segura AG, Mezquida G, Martínez-Pinteño A, Gassó P, Rodriguez N, Moreno-Izco L, et al. Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. *Psychol Med.* 2022 Jun 9;1–14.
3. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. *American Journal of Psychiatry.* 2005 Mar 1;162(3):441–9.
4. Chang WC, Kwong VWY, Chan GHK, Jim OTT, Lau ESK, Hui CLM, et al. Prediction of functional remission in first-episode psychosis: 12-month follow-up of the randomized-controlled trial on extended early intervention in Hong Kong. *Schizophr Res.* 2016 May 1;173(1–2):79–83.
5. Chang WC, Kwong VWY, Or Chi Fai P, Lau ESK, Chan GHK, Jim OTT, et al. Motivational impairment predicts functional remission in first-episode psychosis: 3-Year follow-up of the randomized controlled trial on extended early intervention. *Australian and New Zealand Journal of Psychiatry.* 2018 Feb 23;52(12):1194–201.
6. Rojnic Kuzman M, Makaric P, Bosnjak Kuharic D, Kekin I, Madzarac Z, Koricancic Makar A, et al. General Functioning in Patients With First-Episode Psychosis After the First 18 Months of Treatment. *J Clin Psychopharmacol.* 2020 Jul 1;40(4):366–72.
7. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and Functional Recovery from a First Episode of Schizophrenia or Schizoaffective Disorder. *American Journal of Psychiatry.* 2004 Mar 1;161(3):473–9.
8. Chang WC, Tang JY, Hui CL, Lam MM, Chan SK, Wong GH, et al. Prediction of remission and recovery in young people presenting with first-episode psychosis in Hong Kong: A 3-year follow-up study. *Australian and New Zealand Journal of Psychiatry.* 2012 Feb 6;46(2):100–8.
9. Austin SF, Mors O, Secher RG, Hjorthøj CR, Albert N, Bertelsen M, et al. Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year follow-up. *Schizophr Res.* 2013 Oct 1;150(1):163–8.
10. Mezquida G, Cabrera B, Bioque M, Amoretti S, Lobo A, González-Pinto A, et al. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. *Schizophr Res.* 2017 Nov 1;189:84–90.
11. Rammou A, Fisher HL, Johnson S, Major B, Rahaman N, Chamberlain-Kent N, et al. Negative symptoms in first-episode psychosis: Clinical correlates and 1-year follow-up outcomes in London Early Intervention Services. *Early Interv Psychiatry.* 2019 Jun 1;13(3):443–52.

12. Puig O, Baeza I, De La Serna E, Cabrera B, Mezquida G, Bioque M, et al. Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset. *J Clin Psychiatry*. 2017 Nov 1;78(9):1414–22.
13. Sánchez-Torres AM, Moreno-Izco L, Lorente-Omeñaca R, Cabrera B, Lobo A, González-Pinto AM, et al. Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. *Eur Arch Psychiatry Clin Neurosci [Internet]*. 2018 Oct 1 [cited 2023 Feb 14];268(7):699–711. Available from: <https://link.springer.com/article/10.1007/s00406-017-0857-z>
14. Stouten LH, Veling W, Laan W, van der Helm M, van der Gaag M. Psychosocial functioning in first-episode psychosis and associations with neurocognition, social cognition, psychotic and affective symptoms. *Early Interv Psychiatry [Internet]*. 2017 Feb 1 [cited 2023 Feb 14];11(1):23–36. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/eip.12210>
15. Amoretti S, Ramos-Quiroga JA. Cognitive reserve in mental disorders. *European Neuropsychopharmacology*. 2021;49:113–5.
16. Sánchez-Torres AM, Amoretti S, Enguita-Germán M, Mezquida G, Moreno-Izco L, Panadero-Gómez R, et al. Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study. *Eur Neuropsychopharmacol*. 2023 Feb 1;67:53–65.
17. Dima D, Breen G. Polygenic risk scores in imaging genetics: Usefulness and applications. *Journal of Psychopharmacology*. 2015 Aug 23;29(8):867–71.
18. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. *Hum Mol Genet*. 2019 Nov 21;28(R2):R133–42.
19. Santoro ML, Ota V, de Jong S, Noto C, Spindola LM, Talarico F, et al. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. *Transl Psychiatry*. 2018 Aug;8(1):174.
20. Mistry S, Harrison JR, Smith DJ, Escott-Price V, Zammit S. The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review. *Schizophr Res*. 2018 Jul 1;197:2–8.
21. Sengupta SM, MacDonald K, Fathalli F, Yim A, Lepage M, Iyer S, et al. Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis. *Schizophr Res*. 2017 Jun;184:116–21.
22. Hettige NC, Cole CB, Khalid S, De Luca V. Polygenic risk score prediction of antipsychotic dosage in schizophrenia. *Schizophr Res*. 2016 Feb;170(2–3):265–70.
23. Lee JJ, Wedow R, Okbay A, Kong E, Maghziyan O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet*. 2018 Jul;50(8):1112–21.

24. Escott-Price V, Bracher-Smith, M., Menzies G, Walters J, Kirov G, Owen MJ, O'donovan MC. Genetic liability to schizophrenia is negatively associated with educational attainment in UK Biobank. *Mol Psychiatry*. 2020;25:703–5.
25. Saarentaus EC, Havulinna AS, Mars N, Ahola-Olli A, Kiiskinen TTJ, Partanen J, et al. Polygenic burden has broader impact on health, cognition, and socioeconomic outcomes than most rare and high-risk copy number variants. *Mol Psychiatry*. 2021 Sep;26(9):4884–95.
26. Anaya C, Torrent C, Caballero FF, Vieta E, Bonnín C del M, Ayuso-Mateos JL, et al. Cognitive reserve in bipolar disorder: Relation to cognition, psychosocial functioning and quality of life. *Acta Psychiatr Scand*. 2016;133(5):386–98.
27. Forcada I, Mur M, Mora E, Vieta E, Bartrés-Faz D, Portella MJ. The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. *European Neuropsychopharmacology*. 2015;25(2):214–22.
28. Grande I, Sanchez-Moreno J, Sole B, Jimenez E, Torrent C, Bonnín CM, et al. High cognitive reserve in bipolar disorders as a moderator of neurocognitive impairment. *J Affect Disord*. 2017;208:621–7.
29. Herrero P, Contador I, Stern Y, Fernández-Calvo B, Sánchez A, Ramos F. Influence of cognitive reserve in schizophrenia: A systematic review. Vol. 108, *Neuroscience and Biobehavioral Reviews*. 2020. p. 149–59.
30. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. *Journal of the International Neuropsychological Society*. 2002;8(3):448–60.
31. Amoretti S, Bernardo M, Bonnín CM, Bioque M, Cabrera B, Mezquida G, et al. The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. *European Neuropsychopharmacology*. 2016;26(10):1638–48.
32. Amoretti S, Verdolini N, Mezquida G, Rabelo-da-Ponte FD, Cuesta MJ, Pina-Camacho L, et al. Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. *European Neuropsychopharmacology*. 2021;
33. Barnett JH, Salmond CH, Jones PB, Sahakian BJ. Cognitive reserve in neuropsychiatry. *Psychol Med*. 2006;36(8):1053–64.
34. Camprodón-Boadas P, de la Serna E, Baeza I, Puig O, Ilzarbe D, Sugranyes G, et al. Cognitive reserve in patients with first-episode psychosis as outcome predictor at 5-year follow-up. *Eur Child Adolesc Psychiatry*. 2021 Dec 1;30(12):1959–67.
35. Amoretti S, Cabrera B, Torrent C, Mezquida G, Lobo A, González-Pinto A, et al. Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis. *Acta Psychiatr Scand*. 2018;138(5):441–55.
36. de la Serna E, Andrés-Perpiñá S, Puig O, Baeza I, Bombin I, Bartrés-Faz D, et al. Cognitive reserve as a predictor of two year neuropsychological performance in early onset first-episode schizophrenia. *Schizophr Res*. 2013;143(1):125–31.

37. Camprodón-Boadas P, de la Serna E, Baeza I, Puig O, Ilzarbe D, Sugranyes G, et al. Cognitive reserve in patients with first-episode psychosis as outcome predictor at 5-year follow-up. *Eur Child Adolesc Psychiatry*. 2021 Dec;30(12):1959–67.
38. Amoretti S, Verdolini N, Mezquida G, Rabelo-da-Ponte FD, Cuesta MJ, Pina-Camacho L, et al. Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. *European Neuropsychopharmacology*. 2021;47:112–29.
39. Bernardo M, Bioque M, Parellada M, Ruiz JS, Cuesta MJ, Llerena A, et al. Assessing clinical and functional outcomes in a gene–environment interaction study in first episode of psychosis (PEPs). *Revista de Psiquiatría y Salud Mental (English Edition)*. 2013;6(1):4–16.
40. Bernardo M, Cabrera B, Arango C, Bioque M, Castro-Fornieles J, Cuesta MJ, et al. One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. *Rev Psiquiatr Salud Ment*. 2019;12(3):135–40.
41. Salagre E, Arango C, Artigas F, Ayuso-Mateos JL, Bernardo M, Castro-Fornieles J, et al. CIBERSAM: Ten years of collaborative translational research in mental disorders. *Rev Psiquiatr Salud Ment*. 2019;12(1):1–8.
42. Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A, et al. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. *International Journal of Neuropsychopharmacology*. 2016 Apr 1;19(4).
43. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. *American Journal of Psychiatry*. 2010;167(6):686–93.
44. Mezquida G, Cabrera B, Martínez-Arán A, Vieta E, Bernardo M. Detection of early psychotic symptoms: Validation of the Spanish version of the “Symptom Onset in Schizophrenia (SOS) inventory”. *Psychiatry Res*. 2018 Mar;261:68–72.
45. First M. B, Gibbon M, Spitzer R, Williams J, Benjamin L. Structured clinical interview for DSM-IV axis II personality disorders (SCID-II). Washington, DC: American Psychiatric Press, Inc; 1997.
46. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview For DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc.; 1996.
47. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261–76.
48. Marder SR, Kirkpatrick B. Defining and measuring negative symptoms of schizophrenia in clinical trials. *European Neuropsychopharmacology*. 2014;24(5):737–45.
49. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. *Journal of Clinical Psychiatry*. 1997;58(12):538–46.

50. Amoretti S, Bernardo M, Bonnin CM, Bioque M, Cabrera B, Mezquida G, et al. The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. *European Neuropsychopharmacology*. 2016;26(10):1638–48.
51. Amoretti S, Rosa AR, Mezquida G, Cabrera B, Ribeiro M, Molina M, et al. The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. *Psychol Med* [Internet]. 2022 Feb 9 [cited 2023 Feb 14];52(3):526–37. Available from: <https://www.cambridge.org/core/journals/psychological-medicine/article/abs/impact-of-cognitive-reserve-cognition-and-clinical-symptoms-on-psychosocial-functioning-in-firstepisode-psychoses/7055DDD86330CCE945AF5CC820B31280>
52. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M, Torrent C, Reinares M, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. *Clinical Practice and Epidemiology in Mental Health*. 2007;3:5.
53. Cannon-Spoor HE, Potkin SG, Jed Wyatt R. Measurement of premorbid adjustment in chronic schizophrenia. *Schizophr Bull*. 1982;8(3):470–84.
54. Wechsler D. Wechsler Adult Intelligence Scale - 3rd Edition (WAIS-III). San Antonio, TX: The Psychological Corporation; 1997.
55. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. *Nat Genet*. 2016 Oct;48(10):1284–7.
56. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007 Sep;81(3):559–75.
57. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun*. 2019 Apr;10(1):1776.
58. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018 Oct;562(7726):203–9.
59. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS Genet*. 2006 Dec;2(12):2074–93.
60. Hayes AF, Rockwood NJ. Regression-based statistical mediation and moderation analysis in clinical research: Observations, recommendations, and implementation. *Behaviour research and therapy*. 2017 Nov;98:39–57.
61. Kline RB. The Mediation Myth. *Basic Appl Soc Psych*. 2015;37(4):202–13.
62. Rosseel Y. lavaan: An R Package for Structural Equation Modeling. *J Stat Softw*. 2012 May 24;48(2 SE-Articles):1–36.
63. Bora E. Neurodevelopmental origin of cognitive impairment in schizophrenia. Vol. 45, *Psychological Medicine*. 2015.
64. Walhovd KB, Howell GR, Ritchie SJ, Staff RT, Cotman CW. What are the earlier life contributions to reserve and resilience? *Neurobiol Aging*. 2019 Nov 1;83:135–9.

65. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. *Journal of the International Neuropsychological Society*. 2002;8(3):448–60.
66. de la Serna E, Montejo L, Solé B, Castro-Fornieles J, Camprodón-Boadas P, Sugranyes G, et al. Effectiveness of enhancing cognitive reserve in children, adolescents and young adults at genetic risk for psychosis: Study protocol for a randomized controlled trial. *Rev Psiquiatr Salud Ment*. 2021 Feb;S1888-9891.
67. Barnett JH, Salmond CH, Jones PB, Sahakian BJ. Cognitive reserve in neuropsychiatry. *Psychol Med*. 2006;36(8):1053–64.
68. Green MF, Kern RS, Braff DL, Mint J. Neurocognitive Deficits and Functional Outcome in Schizophrenia: Are We Measuring the “Right Stuff”? [Internet]. Vol. 26, *Schizophrenia Bulletin*. 2000. Available from: <https://academic.oup.com/schizophreniabulletin/article/26/1/119/1927697>
69. Okada H, Hirano D, Taniguchi T. Impact of Negative Symptom Domains and Other Clinical Characteristics on Functional Outcomes in Patients with Schizophrenia. *Schizophr Res Treatment*. 2021;2021.
70. Ventura J, Helleman GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis. *Schizophr Res*. 2009 Sep;113(2–3):189–99.
71. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. *Schizophr Res*. 2012 May;137(1–3):147–50.
72. González-Ortega I, González-Pinto A, Alberich S, Echeburúa E, Bernardo M, Cabrera B, et al. Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. *Psychol Med*. 2020 Dec;50(16):2702–10.
73. Vieta E, Berk M. Early intervention comes late. *Eur Neuropsychopharmacol*. 2022 Jun 1;59:1–3.
74. Konuma T, Okada Y. Statistical genetics and polygenic risk score for precision medicine. *Inflamm Regen*. 2021 Jun;41(1):18.
75. Blanchard JJ, Kring AM, Horan WP, Gur R. Toward the next generation of negative symptom assessments: The collaboration to advance negative symptom assessment in schizophrenia. *Schizophr Bull*. 2011;37(2):291–9.
76. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, et al. The brief negative symptom scale: Psychometric properties. *Schizophr Bull*. 2011;37(2):300–5.
77. Mané A, García-Rizo C, García-Portilla MP, Bergé D, Sugranyes G, García-Alvarez L, et al. Spanish adaptation and validation of the Brief Negative Symptoms Scale. *Compr Psychiatry*. 2014 Oct;55(7):1726–9.

78. Amoretti S, Cabrera B, Torrent C, Bonnín C del M, Mezquida G, Garriga M, et al. Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. *J Clin Med*. 2019;8(5):586.
79. Camprodon-Boadas P, de la Serna E, Baeza I, Ilzarbe D, Puig O, Andrés-Perpiñá S, et al. Psychometric properties of the Cognitive Reserve Questionnaire for Adolescents (CoRe-A). *Rev Psiquiatr Salud Ment*. 2022 Feb 28;
80. Willis KJ, Hakim AM. Stroke prevention and cognitive reserve: emerging approaches to modifying risk and delaying onset of dementia. *Front Neurol*. 2013;4:13.

Financial support

The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.


Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding authors.


Figure 1. Parallel mediation model. The mediating effect of three mediators (CR, PS and NS) in the relationship between PRS_{EA} and functionality.



All presented effects are unstandardized. C' is the direct effect of PRS_{EA} on functionality. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Continuous lines denoted significant regression.

Abbreviations: CR=Cognitive Reserve; PS=Positive Symptoms; NS=Negative Symptoms; PRS_{EA} =Polygenic risk score for educational attainment

Figure 2. The serial mediating effect of CR, PS and NS in the relationship between PRS_{EA} and functionality.



All presented effects are unstandardized. C' is the direct effect of PRS_{EA} on functionality. *p<0.05, **p<0.01, ***p<0.001. Continuous lines denoted significant regression. Grey lines represent path with significant indirect effect.

Abbreviations: CR=Cognitive Reserve; PS=Positive Symptoms; NS=Negative Symptoms; PRS_{EA}=Polygenic risk score for educational attainment

Table 1. Main sociodemographic, functional and clinical features of the FEP sample at study entry (N = 162)

Sociodemographic variables (Mean±SD or n (%))	
Sex (Male/Female)	113(70)/49(30)
Age (years)	24.7±5.4
Age at onset (years)	24.6±5.4
Duration of untreated psychosis (days)	98.7±128.2
Educational level	
No education	1 (0.6)
Primary education	27 (16.7)
Lower secondary education	63 (38.9)
Upper secondary and non-tertiary education	41 (25.3)
University	29 (17.9)
Others	1 (0.6)
Chlorpromazine equivalents	577.8±489.5
Cannabis (yes)	73(44)
Tobacco (yes)	116(69)
Clinical and functional variables at baseline (Mean±SD)	
Positive Marder PANSS Factor	20.8±8.4
Negative Marder PANSS Factor	18.2±8.0
Functionality (FAST)	27.7±16.3
Cognitive Reserve	75.9±11.8
Clinical and functional variables at one-year follow-up (Mean±SD)	
Positive Marder PANSS Factor	12.4±5.3
Negative Marder PANSS Factor	14.1±6.4
Functionality (FAST)	18.2±14.9

Abbreviations: FAST= Functioning Assessment Short Test. PANSS = Positive and Negative Syndrome Scale.

Table 2. Non-standardized total, direct and indirect effects (total and of each individual mediator or path) of the two mediation models.

	β	[95% CI]	p-value
1. Parallel Mediation Model			
Total Effect	-3.08	[-5.34, -0.74]	0.008
Direct Effect	-1.37	[-3.22, 0.48]	0.145
Total Indirect Effect	-1.71	[-3.35, -0.07]	<0.05
CR Indirect Effect	-0.13	[-0.59, 0.22]	>0.05
PS Indirect Effect	-0.7	[-0.97, 0.12]	>0.05
NS Indirect Effect	-1.21	[-2.77, 0.13]	>0.05
2. Serial Mediation Model			
Total Effect	-3.08	[-5.34, -0.74]	0.008
Direct Effect	-1.37	[-3.22, 0.48]	0.145
Total Indirect Effect	-1.71	[-3.35, -0.07]	<0.05
PRSE _{EA} >CR >Functionality	-0.13	[-0.59, 0.23]	>0.05
PRSE _{EA} >PS >Functionality	-0.09	[-0.57, 0.51]	>0.05
PRSE _{EA} >NS >Functionality	-0.86	[-2.42, 0.52]	>0.05
PRSE _{EA} >CR >PS >Functionality	-0.08	[-0.24, 0.01]	>0.05
PRSE _{EA} >CR >NS >Functionality	-0.35	[-0.85, -0.04]	<0.05
PRSE _{EA} >NS >PS >Functionality	-0.18	[-0.55, 0.14]	>0.05
PRSE _{EA} >CR >NS >PS >Functionality	-0.07	[-0.21, 0.00]	>0.05

Abbreviations: CI= Confidence interval; CR= Cognitive Reserve; PS= Positive Symptoms; NS= Negative Symptoms; PRSE_{EA} = polygenic risk score for educational attainment